Objective. To assess the efficiency and tolerability of the Mardil Zinc Max, solution for external application, in topical therapy of patients with anogenital warts. Materials and methods. The study involved 58 women and 12 men at the age of 18 to 57 years old, suffering from anogenital warts. the diagnosis was confirmed by identification of human papillomavirus by the polymerase chain reaction in real time. All the patients were treated by the chemical destruction of anogenital warts with the 1.5% solution of zinc chloropropionate in 50% 2-chloropropionic acid (Mardil Zinc Max) by a single application of the solution on the pathological eruptions. The results of treatment were assessed in 2 weeks, in 1, 3, 6 and 9 months after the destructive therapy. Results. In 2 weeks 62 (88.6%) patients showed a clinical cure with complete tissue regeneration in the lesions, in 8 (11,4%) cases in areas of the preparation erosions were visualized in the epithelialization phase, and they completely resolved within 1 week. recurrences of anogenital warts were detected in 1 (1,4%) patient in the observation period up to 3 months and in 2 (2,8%) patients during 9 months after carrying out the destruction. Adverse drug events have not been identified in the course of therapy and follow-up. Conclusions. As a result of the treatment of anogenital warts with the Mardil Zinc Max high rate of performance and security was set (100%), as well as the low percentage (4,2%) of development of relapses.
Represents results of research, dedicated to the search of genetically determined factors of С. trachomatis virulence. Data of papers, studying features of С. trachomatis genetic variations was highlighted.
The article covers issues of ethiology and pathogenesis of papilloma viral infection, modern perceptions of the role of immune mechanisms in the development of the infection process. Were submitted results of the comparative clinical research for the study of efficiency and safety of Ingaron substance (γ-interferon) in the comprehensive therapy of the anogenital papilloma viral infection.
The authors present the results of studies of risk factors at the contamination with С. trachomatis and of the development of complicated forms of the urogenital chlamydial infection at men, modern peculiarities of the clinical course of the urogenital chlamydiosis have been reflected. Goal: studies of factors of the risk of contamination with С. trachomatis and development of aggravates forms of urogenital chlamydial infection and the analysis of modern clinical peculiarities of the disease in men of the reproductive age. Маterials and methods. 40 men were examined, among them 20 with urogenital chlamydial infection of lower segments of the genitourinary tract and 20 with complicated forms of urogenital chlamydial infection. The group of comparison comprised 20 men, not having clinical and laboratory features of sexually transmitted diseases and inflammatory diseases of the urogenital tract. Along with the analysis of anamnesis data of the clinical picture was performed the instrumental (transrectal ultrasonic research of the prostate) and the laboratory examination, using the microscopic, bacteriologic and molecular and biologic methods. Results. The authors established factors of risk of the contamination with urogenital chlamydial infection (age between 25 and 39 y.o., existent sexual contacts with two and more sexual partners, big number of sexual partners during the sexual practice) and factors of the risk of development of complicated forms of the chlamydial infection (patient age between 25 and 45 y.o. and the disease, lasting for more than 1 month). Main clinical implications of chlamydial urethritis and prostatitis are described.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.